Substances · Cathinone derivatives
N-Ethylhexedrone (Hexen)
- Preferred name
- N-Ethylhexedrone (Hexen)
- IUPAC name
- 2-(ethylamino)-1-phenylhexan-1-one
- Parent CAS number (reference)
- 802857-66-5
- Molecular formula
- C14H21NO
- Molecular weight
- 219.32 g/mol
- InChIKey
- CWNKMHIETKEBCA-UHFFFAOYSA-N
- PubChem
- CID 134822125
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
N-Ethylhexedrone Hexen NEH Ethyl-Hexedrone
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
N-Ethylhexedrone (Hexen / NEH)
Receptor Telemetry & Mechanism of Action
Potent, selective norepinephrine-dopamine reuptake inhibitor (NDRI) without monoamine-releasing activity. Extending the alpha-side chain by one carbon over NEP increases dopamine uptake blockade >3.5-fold: in HEK293 assays (Eshleman et al., 2019), hDAT IC50 = 46.7 ± 4.0 nM (Ki = 171 ± 38 nM) and hNET IC50 = 97.8 ± 8.3 nM (Ki = 1,259 ± 43 nM), with ~100-fold weaker serotonin inhibition (hSERT IC50 = 4,880 ± 470 nM, Ki = 11,400 ± 1,800 nM). Also exhibits moderate local anesthetic activity and elevated in vitro cytotoxicity in SH-SY5Y neuronal cells.
Biotransformation & Active Metabolites
WHO 42nd ECDD reports mucosal onset within ~2 minutes (peaking at 20–25 minutes) and oral onset at 20–25 minutes (peaking at 50–60 minutes); formal human elimination half-life is unverified.
Temporal Pharmacokinetics
Sharp, hard-hitting dopaminergic rush with moderate local numbing, rapid thought acceleration, ego inflation, and prominent cardiovascular and vasoconstrictive load.
- Onset 20–25 minutes oral (2–8 minutes mucosal)
- Peak Window 50–60 minutes oral (20–90 minutes mucosal)
- Total Window 3–6 hours oral (2–5 hours mucosal)
- Residual / Half-Life 1–8 hours (longer after repeated exposure) of persistent tachycardia, cold extremities, anxiety, and insomnia; human plasma half-life is unverified.
Steep response curve: above 30–40 mg mucosal or 40–50 mg orally, mood elevation is rapidly overtaken by persistent tachycardia, cold hands/feet, and anxiety. Hexen is notorious for a brief 30–60 minute mood-elevating rush followed by up to 8 hours of lingering peripheral adrenergic stimulation—making repeated exposure binges rapidly toxic and exhausting.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
5–15 mg oral (5 mg mucosal)
Crisp mental awakening, subtle focus enhancement, and mild alertness.
Slight heart-rate increase and mild mouth/nasal numbing if mucosal.
15–25 mg oral (PsychonautWiki 5–24 mg / TripSit 15–30 mg mucosal)
Functional concentration, heightened motivation, talkativeness, and clean mood lift.
Noticeable pulse increase, appetite suppression, dry mouth, and light sweating.
25–40 mg oral (24–30 mg PW / 30–40 mg TripSit mucosal)
Strong mood-elevating rush, ego inflation, music immersion, disinhibition, and fierce urge to redose as the rush ebbs.
Pronounced and prolonged tachycardia, elevated blood pressure, cold hands and feet (vasoconstriction), and nasal mucosal irritation.
40–50 mg oral (30–40 mg PW / 40–50 mg TripSit mucosal)
Scattered hyper-stimulation, impaired concentration, jittery restlessness, anxiety, and compulsive repeated exposure.
Heavy palpitations, chest tightness, bruxism, nausea, tremors, and temporary erectile dysfunction.
50+ mg oral (40–50+ mg mucosal)
Acute panic, auditory distortions/hallucinations, paranoia, and binge-induced stimulant psychosis.
Severe hypertension, dangerous arrhythmias, peripheral vasospasm, hyperthermia, and seizures.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
High-affinity dopamine/norepinephrine reuptake blockade paired with MAO inhibition causes fatal hypertensive crisis and arrhythmias.
Additive NDRI cardiac load and severe vasoconstriction create acute risk of myocardial ischemia, stroke, and seizures.
Markedly lowers seizure threshold alongside intense adrenergic stimulation.
Elevated Hazard — Avoid
Exacerbates Hexen's notoriously prolonged heart-rate elevation, hyperthermia, and neurotoxicity.
Masks depressant intoxication, worsens dehydration and cardiovascular stress, and has been co-detected in severe forensic poisonings.
Caution / Receptor Attenuation
Strongly amplifies resting tachycardia, chest anxiety, and paranoid thought loops during Hexen's long adrenergic tail.
Worsens vasoconstriction (cold extremities) and jittery palpitations.
Structural Isomer & Sibling Comparison
Hexen (NEH) is ~3.5-fold more potent at blocking DAT than NEP (hDAT IC50 46.7 nM vs. 165 nM), delivering a sharper, more rush-driven peak with moderate local numbing, but at the cost of stronger vasoconstriction, more persistent heart-rate elevation, and a rougher comedown than NEP. Compared to alpha-PHP (its pyrrolidino analogue), Hexen requires roughly twice the milligram amount (common 25–40 mg vs. 10–25 mg).
Physicochemical Stability & Storage
Physical Form: Fine white to off-white crystalline powder or needles as the hydrochloride salt, producing moderate topical mouth/nasal numbing and mucosal irritation. · Soluble in water, ethanol, methanol, DMF, and DMSO.
Store sealed, dry, and protected from light and heat.
Cross-Tolerance & Dependence Profile
Rapid acute tolerance to mood elevation within 2–3 doses; full cross-tolerance with NEP, cocaine, pyrovalerones, and amphetamines (3–7 days to halve, 1–2 weeks to baseline). High psychological addiction liability driven by compulsive binge repeated exposure.
Spot-test and isomer verification
Spot-test notes for hexen. Marquis and Mecke stay colourless and non-reactive, which rules out MDMA and amphetamines. Simon's turns cobalt-blue on the secondary amine. Zimmermann turns reddish-purple to violet on the β-ketone, and Morris shifts blue-violet.
Colorimetric spot tests (SWGDRUG Category C) and standard low-resolution EI-MS (m/z 58 iminium base peak) cannot separate N-alkyl chain homologues such as NEP and hexen; definitive differentiation requires ATR-FTIR, Raman, chromatographic retention matching (GC-MS or LC-MS), or ¹H-NMR.
Codes on this card
Short meanings for the abbreviations printed with this substance.
DAT
Dopamine transporter
DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.
NET
Norepinephrine transporter
NET is the protein that collects norepinephrine, also called noradrenaline, back into the nerve cell. Cards cite it when a lab report shows activity at that transporter.
SERT
Serotonin transporter
SERT is the protein that collects serotonin back into the nerve cell. A higher number than at DAT means the serotonin transporter needed more concentration to reach the halfway point.
SNDRA / NDRI
Releaser or reuptake blocker
An SNDRA is carried in and the cell releases serotonin, norepinephrine, and dopamine. An NDRI mainly slows the vacuum at norepinephrine and dopamine. The class line says which one the papers describe.
EC₅₀ / IC₅₀
Halfway concentration
EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.
ratio
Selectivity ratio
A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.
5-HT ↑↑
Serotonergic Overload (Serotonin Toxicity)
A potentially fatal medical emergency caused by excessive synaptic serotonin (for example when mixing two serotonin releasers, MAOIs, or tramadol), marked by hyperthermia and neuromuscular rigidity.
HR / Naczynia
Vasoconstriction & Cardiovascular Load
Narrowing of peripheral blood vessels, elevated blood pressure, and rapid heart rate driven by strong noradrenergic and dopaminergic stimulation.
Chemical Architecture & Structural Profile
N-Ethylhexedrone (Hexen) (2-(ethylamino)-1-phenylhexan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C14H21NO and a molar mass of 219.32 g/mol. The parent molecule is indexed under CAS registry number 802857-66-5 and in the NCBI PubChem database as CID 134822125 (Standard InChIKey: CWNKMHIETKEBCA-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), N-Ethylhexedrone (Hexen) is indexed within the Cathinone structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): moderately addictive with a high potential for abuse. Documented cross-tolerance class: norepinephrine|noradrenergic, dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- Gesetze im Internet — Neue-psychoaktive-Stoffe-Gesetz (NpSG) & BtMG — Bundesministerium der Justiz (2026-11-12)